New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
10:57 EDTARWR, CREE, PSEC, TAX, OPK, YPF, CALL, KING, ICPT, ACRXOptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT KING CALL YPF OPK TAX PSEC CREE ACRX
News For ARWR;ICPT;KING;CALL;YPF;OPK;TAX;PSEC;CREE;ACRX From The Last 14 Days
Check below for free stories on ARWR;ICPT;KING;CALL;YPF;OPK;TAX;PSEC;CREE;ACRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 17, 2014
14:54 EDTARWRArrowhead Research November volatility elevated into Phase IIb trial data
Subscribe for More Information
07:36 EDTARWRArrowhead outlook positive, says RBC Capital
Subscribe for More Information
September 16, 2014
09:03 EDTCREECree files lawsuits to protect LED component intellectual property
Subscribe for More Information
September 15, 2014
11:40 EDTCREECree drops, levels to watch
Subscribe for More Information
11:06 EDTACRXOptions with increasing implied volatility
Subscribe for More Information
09:59 EDTCREEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTCREEOn The Fly: Pre-market Movers
Subscribe for More Information
09:14 EDTOPKOPKO Health launches 4Kscore Test in Europe
Subscribe for More Information
05:37 EDTCREEAcuity Brands upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Acuity Brands to Buy saying growth in the company's LED lighting business is averaging over two-times the industry. Goldman is bullish on LED lighting adoption and raised its price target for shares to $153 from $128. The firm coupled the upgrade of Acuity with a downgrade of Cree (CREE) to Neutral.
05:35 EDTCREECree downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Cree (CREE) to Neutral citing slowing growth in the company's chip business. Goldman lowered its price target for Cree shares to $48 and $60 and prefers Acuity Brands (AYI) as an LED lighting investment. Shares of Cree closed Friday down 57c to $42.67. Goldman upgraded Acuity Brands this morning to Buy.
September 12, 2014
10:00 EDTCREEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
September 11, 2014
18:12 EDTCREECree initiated with a Market Perform at Cowen
Subscribe for More Information
11:29 EDTPSECOptions with increasing implied volatility
Options with increasing implied volatility: VNET AVNR GPRO RAX FTR JDSU PSEC APD SYY GGP
09:03 EDTOPKOPKO announces publication of MOD-4023 Phase 2 dose finding study
OPKO Health announced that the abstract “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone: Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency" has been selected for late breaking oral presentation at the 53rd Annual Meeting of the European Society of Paediatric Endocrinology on September 20. OPKO will present six month efficacy, safety, pharmacokinetic and pharmacodynamics data from the company's advanced phase 2 trial for its long acting human growth hormone hGH-CTP, or MOD-4023, in growth hormone deficient pediatric subjects. In addition, OPKO’s posters to be presented during the conference have been recognized for outstanding advancement by ESPE and will introduce additional data, as well as analytical characteristics of hGH-CTP in preparation for the planned pediatric phase 3 study. The data from this study supported once-weekly dosing for hGH-CTP and also enabled the selection of an appropriate dose to demonstrate non-inferiority compared to daily hGH in the upcoming phase 3 study. hGH-CTP demonstrated a good safety and tolerability profile in this ongoing study.
07:28 EDTPSECPR Newswire to hold a virtual conference
Subscribe for More Information
September 9, 2014
10:13 EDTCREECree calls active on takeover speculation
Subscribe for More Information
09:52 EDTCREERumor: Cree strength attributed to takeover speculation
September 8, 2014
12:22 EDTOPKOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
September 5, 2014
10:05 EDTICPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
06:30 EDTICPTIntercept initiated with an Outperform at Cowen
Target $420.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use